Eloxx Pharmaceuticals
Biotechnology Research • 
Watertown, Massachusetts, United States • 11-20 Employees
Company overview
| Headquarters | 480 Arsenal Way Suite 130, Watertown, Massachusetts 02472, US |
| Phone number | +17815775300 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Healthcare, Biotech, Life Sciences, Pharmaceuticals, Rare Diseases, Drug Development |
| Founded | 2013 |
| Employees | 11-20 |
| Socials |
Key Contacts at Eloxx Pharmaceuticals
He Zhao
Director Of Chemistry And Head Of Drug Substance
Israela Ronen
Senior Director Finance
Joe Shi
Associate Director/Senior Research Fellow
Eloxx Pharmaceuticals Email Formats
Eloxx Pharmaceuticals uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@eloxxpharma.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@eloxxpharma.com | 50% |
{first initial}.{last name} | j.doe@eloxxpharma.com | 40% |
{first initial}{last name} | jdoe@eloxxpharma.com | 10% |
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Eloxx Pharmaceuticals revenue & valuation
| Annual revenue | $3,578,448 |
| Revenue per employee | $299,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $11,500,000 |
| Total funding | $2,000,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Eloxx Pharmaceuticals has 7 employees across 5 departments.
Departments
Number of employees
Eloxx Pharmaceuticals Tech Stack
Discover the technologies and tools that power Eloxx Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress plugins
Analytics
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
UI frameworks
SEO
Tag managers
Germany
Australia
South AfricaFrequently asked questions
4.8
40,000 users
